市场调查报告书
商品编码
1468146
2024-2032 年肾癌治疗和诊断市场报告(按成分、癌症类型、应用和地区)Kidney Cancer Therapeutics and Diagnostics Market Report by Component, Cancer Types, Application, and Region 2024-2032 |
IMARC Group年,全球肾癌治疗及诊断市场规模达51亿美元。肾癌发病率上升、老年人口增加以及多个政府的有利倡议是推动市场发展的一些关键因素。
肾癌是一种慢性疾病,肾组织中细胞异常生长,进而转变为肿瘤。其症状包括尿血、食慾不振、腰痛、疲倦、发烧、体重减轻、骨痛、高血压和贫血。肾癌可透过多种技术诊断,例如血液和尿液检查、活检、生物标记测试、电脑断层扫描(CT) 扫描、X 光、磁振造影(MRI)、膀胱镜检查和肾单位输尿管镜检查。它可以透过药物、化疗、放射治疗、肾切除术、冷冻消融、射频消融和标靶治疗来治疗。肾癌治疗和诊断有助于清除癌细胞、破坏肿瘤并防止復发,并协助医生规划治疗方案。它们还有助于改善肾功能、减少未来的併发症、控制癌症扩散并提高患者的舒适度。
由于吸烟习惯、肥胖、遗传条件和化学物质接触的日益普遍,肾癌发病率不断上升,这是推动市场成长的主要因素之一。肾癌治疗和诊断广泛用于分析和治疗肾细胞癌(RCC)、良性肾肿瘤、肾母细胞瘤、移行细胞癌、肾肉瘤、髓样癌、多房性囊性肾细胞癌以及黏液性管状细胞癌和梭形细胞癌。此外,对肾细胞癌和其他形式肾癌高度易感的老年人口不断增加,促进了对治疗和诊断的需求,以控制肿瘤、延长生存期和保护肾臟的非癌症部分。此外,最近开发的能够检测生物标记的诊断工具,例如桿状病毒 IAP 重复序列 5 (BIRC5),是早期检测透明细胞肾细胞癌和预测患者预后的关键指标,正在对市场成长产生积极影响。除此之外,引入三维 (3D) 列印来创建肾臟及其肿瘤的术前模型,从而帮助医生製定治疗计划并为患者提供适当的咨询,减少手术错误,增强效率和保留大部分肾功能有利于市场成长。此外,政府实施的各种旨在传播癌症意识的措施正在为市场创造积极的前景。预计其他因素包括医疗保健行业的显着增长、为确定潜在治疗方案而对研发 (R&D) 活动的投资不断增加,以及机器人手术、远距医疗和人工智慧 (AI) 等先进技术的广泛采用以进一步推动市场成长。
The global kidney cancer therapeutics and diagnostics market size reached US$ 5.1 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 8.8 Billion by 2032, exhibiting a growth rate (CAGR) of 6.22% during 2024-2032. The rising incidences of kidney cancer, increasing geriatric population, and favorable initiatives by several governments represent some of the key factors driving the market.
Kidney cancer is a chronic disease where abnormal cell growth occurs in kidney tissues, which turns into tumors. Its symptoms include blood in urine, loss of appetite, flank pain, tiredness, fever, weight loss, bone pain, high blood pressure, and anemia. Kidney cancer is diagnosed through various techniques, such as blood and urine tests, biopsy, biomarker testing, computed tomography (CT) scan, X-ray, magnetic resonance imaging (MRI), cystoscopy, and nephron-ureteroscopy. It can be treated through medications, chemotherapy, radiation therapy, nephrectomy, cryoablation, radiofrequency ablation, and targeted therapy. Kidney cancer therapeutics and diagnostics aid in the removal of cancer cells, destroy tumors and prevent recurring, and assist physicians in planning treatments. They also help in improving kidney function, reducing future complications, controlling cancer spread, and enhancing patient comfort.
The rising incidences of kidney cancer due to the increasing prevalence of smoking habits, obesity, genetic conditions, and exposure to chemicals is one of the primary factors driving the market growth. Kidney cancer therapeutics and diagnostics are widely used to analyze and treat renal cell carcinoma (RCC), benign kidney tumors, Wilms tumors, transitional cell cancer, renal sarcoma, medullary carcinoma, multilocular cystic RCC, and mucinous tubular and spindle cell carcinoma. Furthermore, the rising geriatric population with high susceptibility to renal cell carcinoma and other forms of kidney cancer is facilitating the demand for therapeutics and diagnostics to manage tumors, prolong survival, and preserve noncancerous parts of the kidney. Additionally, the recent development of diagnostic tools capable of detecting biomarkers, such as baculoviral IAP repeat containing 5 (BIRC5), a key indicator for early detection of clear cell RCC and predicting patient prognosis, is positively influencing the market growth. Apart from this, the introduction of three-dimensional (3D) printing to create pre-operative models of the kidney and its tumors, which, in turn, aids physicians in treatment planning and providing appropriate counseling to the patients, reducing surgical errors, enhancing efficiency, and preserving the majority of kidney functions are favoring the market growth. Moreover, the implementation of various government initiatives to spread awareness regarding cancer is creating a positive outlook for the market. Other factors, including significant growth in the healthcare industry, rising investment in research and development (R&D) activities to identify potential treatment options, and widespread adoption of advanced technologies, such as robotic surgery, telemedicine, and artificial intelligence (AI), are anticipated to drive the market growth further.
IMARC Group provides an analysis of the key trends in each segment of the global kidney cancer therapeutics and diagnostics market, along with forecasts at the global, regional, and country level from 2024-2032. Our report has categorized the market based on component, cancer types, and application.
Drugs
Drugs by Therapeutic Class
Targeted Therapy
Immunotherapy
Others
Drugs by Pharmacologic Class
Angiogenesis Inhibitors
mTOR Inhibitors
Monoclonal Antibodies
Cytokine Immunotherapy (II-2)
Diagnostics
Imaging Test
Biopsy
Blood Test
Others
The report has also provided a detailed breakup and analysis of the kidney cancer therapeutics and diagnostics market based on the component. This includes drugs (therapeutic class (targeted therapy, immunotherapy, and others) and pharmacological class (angiogenesis inhibitors, mTOR inhibitors, monoclonal antibodies, and cytokine immunotherapy (II-2) and diagnostics (imaging test, biopsy, blood test, and others). According to the report, drugs represented the largest segment.
Clear Cell RCC
Papillary RCC
Chromophobe RCC
Transitional Cell Carcinoma
Others
A detailed breakup and analysis of the kidney cancer therapeutics and diagnostics market based on the cancer types has been provided in the report. This includes clear cell RCC, papillary RCC, chromophobe RCC, transitional cell carcinoma, and others. According to the report, clear cell RCC accounted for the largest market share.
Hospitals
Pharmaceutical Labs
Genomic Laboratories
Others
A detailed breakup and analysis of the kidney cancer therapeutics and diagnostics market based on the application has been provided in the report. This includes hospitals, pharmaceutical labs, genomic laboratories, and others. According to the report, hospitals accounted for the largest market share.
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The report has also provided a comprehensive analysis of all the major regional markets that include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and Middle East and Africa. According to the report, North America was the largest market for kidney cancer therapeutics and diagnostics. Some of the factors driving the North America kidney cancer therapeutics and diagnostics market include increasing incidences of kidney cancer, rising research and development (R&D) expenditure, increasing geriatric population, etc.
The report has also provided a comprehensive analysis of the competitive landscape in the global kidney cancer therapeutics and diagnostics market. Detailed profiles of all major companies have also been provided. Some of the companies covered include Bristol-Myers Squibb Company, Exelixis Inc., Genentech Inc. (Roche Holding AG), Novartis AG, Pfizer Inc., etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.